Plasma β‐synuclein associates with hippocampal synaptic density measured with [11C]UCB‐J PET and plasma tau markers in Alzheimer’s disease

by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia

Abstract INTRODUCTION Plasma β-synuclein is a promising blood-based synaptic biomarker, but relationships with synaptic density as indicated by [11C]UCB-J positron emission tomography (PET), and blood biomarkers of Alzheimer’s disease (AD) pathology,...

Cost‐effectiveness of lecanemab for early Alzheimer’s disease in China

by Clinical Neuropsychologist Online | Wednesday, October 28, 2026 | Dementia

Abstract BACKGROUND Although lecanemab has demonstrated clinical efficacy in early Alzheimer’s disease (AD), its cost-effectiveness in China remains uncertain. This study evaluated the long-term cost-effectiveness of lecanemab in Chinese patients from a societal...

Pathway‐specific polygenic risk scores modify the association between amyloid and tau PET accumulation in patients with Alzheimer’s disease

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia

Abstract BACKGROUND Genome-wide association studies (GWASs) identified multiple genetic variants associated with Alzheimer’s disease (AD) risk, yet the biological pathways linking these to amyloid and tau pathology remain unclear. METHODS We conducted a...

Phase 3 randomized trial of latozinemab in frontotemporal dementia due to GRN mutations

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia

Abstract INTRODUCTION Heterozygous progranulin gene mutations causing frontotemporal dementia (FTD-GRN) are associated with deficiency in progranulin (PGRN). Latozinemab is a human monoclonal immunoglobulin G1 (IgG1) antibody designed to elevate PGRN levels in people...

Real‐world clinical, biomarker, and imaging outcomes of lecanemab in Alzheimer’s disease: a multicenter longitudinal cohort study in Jiangsu, China

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia

Abstract INTRODUCTION Real-world data on lecanemab’s efficacy and the longitudinal dynamics of plasma biomarkers are scarce in Chinese patients with Alzheimer’s disease (AD). METHODS In this multicenter cohort study, 181 AD patients received biweekly...

Brains for dementia research at 18: Commitment to impact the value of human post‐mortem tissue

by Clinical Neuropsychologist Online | Tuesday, October 27, 2026 | Dementia

Abstract The Brains for Dementia Research (BDR) project was established to provide high quality, neuropathologically characterized post-mortem brain tissue from a cohort of participants longitudinally assessed for outcomes that are relevant for research in relation to...